Capsule Summary Slides


Share

Program Content

Activities

  • KEYNOTE-826 Final Analysis
    KEYNOTE-826: Final OS Analysis of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Persistent, Recurrent, or Metastatic Cervical Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2023

  • MIRASOL
    MIRASOL: Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in FRα-High Expression, Platinum-Resistant Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2023

  • DUO-O
    DUO-O: First-line CT + Bevacizumab ± Durvalumab Followed by Maintenance Bevacizumab ± Durvalumab With or Without Olaparib in Newly Diagnosed Advanced Ovarian Cancer Without Tumor BRCA Mutation
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2023

  • SHAPE
    SHAPE: Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Low-Risk Early-Stage Cervical Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2023

  • RUBY Dostarlimab + CT
    ENGOT-EN6-NSGO/GOG3031/RUBY: Outcomes by BICR With Addition of Dostarlimab to Carboplatin/Paclitaxel for Advanced or Recurrent Endometrial Cancer
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • RUBY: HRQoL With Dostarlimab + CP in EC
    ENGOT-EN6-NSGO/GOG-3031/RUBY: PROs With Addition of Dostarlimab to  Carboplatin/Paclitaxel for Advanced or Recurrent Endometrial Cancer
    Capsule Summary
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, GSK, and Merck Sharp & Dohme Corp.

AstraZeneca

GSK

Merck Sharp & Dohme Corp.